IPHA Overview

Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.

Wall Street analysts forecast IPHA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IPHA is6.50 USD with a low forecast of 5.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Innate Pharma SA revenue for the last quarter amounts to NaN USD, decreased

Innate Pharma SA. EPS for the last quarter amounts to USD, decreased

Innate Pharma SA (IPHA) has 181 emplpoyees as of February 16 2026.

Today IPHA has the market capitalization of 163.08M USD.